Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6757-6769

  Khanna, Anchit ^a,g   Kauko, Otto ^b   Böckelman, Camilla ^c,d   Laine, Anni ^b   Schreck, Ilona ^f   Partanen, Johanna I ^d   Szwajda, Agnieszka ^e   Bormann, Stefanie ^f   Bilgen, Turker ^b,h   Helenius, Merja ^a   Pokharel, Yuba R ^b   Pimanda, John ^g   Russel, Mike R ⁱ   Haglund, Caj ^c   Cole, Kristina A ^i,j   Klefström, Juha ^d   Aittokallio, Tero ^e   Weiss, Carsten ^f   Ristimäki, Ari ^c,d   Visakorpi, Tapio ^a   Westermarck, Jukka ^b   more..

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h AKDENIZ UNIVERSITY   (Turkey)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CANCEROUS INHIBITOR OF PHOSPHOPROTEIN PHOSPHATASE 2A; CHECKPOINT KINASE 1; DNA DEPENDENT PROTEIN KINASE; MYC PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL SURVIVAL; CLONOGENIC ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

AUTOANTIGENS; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN PHOSPHATASE 2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84888344463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1002     Document Type: Article

References (37)

1. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603.
2. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007;130:21-4.
3. Sablina AA, Hahn WC. SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 2008;27: 137-46.
4. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130: 51-62.
5. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010;29:6257-66.
6. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-Bourgeois C, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 2010;40:863-76.
7. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013;3:182-97.
8. Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012;31:4266-78.
9. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009;15:5092-100.
10. Mathiasen D, Egebjerg C, Andersen S, Rafn B, Puustinen P, Khanna A, et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 2011;31:390-401.
11. Ventela S, Come C, Makela JA, Hobbs RM, Mannermaa L, Kallajoki M, et al. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PLoS One 2012;7:e33209.
12. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009;101:793-805.
13. Basu B, Yap TA, Molife LR, de Bono JS. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol 2012;24:316-24.
14. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNAdamage signaling and cancer. Adv Cancer Res 2010; 108:73-112.
15. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011;18:1331-5.
16. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012;31:1661-72.
17. Tho LM, Libertini S, Rampling R, Sansom O, Gillespie DA. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene 2012;31:1366-75.
18. Hoglund A, Nilsson LM, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res 2011;17: 7067-79.
19. Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res 2012;18:5650-61.
20. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 2011;108:3336-41.
21. Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, et al. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 2010;29: 4007-17.
22. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Develop 2000;14:1448-59.
23. Lopez-Contreras AJ, Gutierrez-Martinez P, Specks J, Rodrigo-Perez S, Fernandez-Capetillo O. An extra alletle of Chk1 limits oncogene-induced replicative stress and promotes transformation. J Exp Med 2012;209:455-61.
24. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17: 88-96.
25. Partanen JI, Nieminen AI, Makela TP, Klefstrom J. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci U S A 2007;104:14694-9.
26. Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010;126:2012-24.
27. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damageinduced transcriptional repression. Cell 2008;132:221-32.
28. Blasius M, Forment JV, Thakkar N, Wagner SA, Choudhary C, Jackson SP. A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1. Genome Biol 2011;12:R78.
29. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011;6:e17979.
30. Berthon P, Cussenot O, Hopwood L, Le Duc A, Maitland NJ. Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines. Int J Oncol 1995;6:333-43.
31. Kim J, Lee JH, Iyer VR. Global identi fication of Myctarget genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One 2008;3:e1798.
32. Bretones G, Acosta JC, Caraballo JM, Ferrandiz N, Gomez-Casares MT, Albajar M, et al. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells. J Biol Chem 2011;286:9815-25.
33. Wilsker D, Petermann E, Helleday T, Bunz F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci U S A 2008;105:20752-7.
34. Li J, Stern DF. Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 2005;280:12041-50.
35. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481:287-94.
36. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
37. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009;33:537-45.